Article Text

other Versions

PDF
Research paper
Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study
  1. Philippe Cabre1,
  2. Stephane Olindo1,
  3. Romain Marignier2,
  4. Severine Jeannin1,
  5. Harold Merle3,
  6. Didier Smadja1,
  7. under the Aegis of the French National Observatory of Multiple Sclerosis
  1. 1Department of Neurology, CHRU Pierre Zobda-Quitman, Fort de France, Martinique, French West Indies
  2. 2Department of Neurology A, Pierre Wertheimer Hospital, Civilian Hospices of Lyon, Lyon, France
  3. 3Department of Ophthalmology, CHRU Pierre Zobda-Quitman, Fort de France, Martinique, French West Indies
  1. Correspondence to Dr Philippe Cabre, Department of Neurology, CHRU Pierre Zobda-Quitman, Fort de France, Martinique 97261, French West Indies; pcabre_fr{at}yahoo.fr

Abstract

Objective To evaluate the efficacy of mitoxantrone (MTX) on clinical and neuroradiological parameters of patients who had a relapse of neuromyelitis optica spectrum (NMOS) within the 12 previous months.

Methods MTX (12 mg/m2) combined with methylprednisolone 1 g as three monthly courses followed by three quarterly courses was administered during an observational multicentre open study including 51 consecutive patients (28 NMO, 23 limited forms of NMO) of the French Caribbean and Guyana. The main outcome measure was the reduction of the annualised relapse rate (ARR), and the secondary outcome measures were alteration of disability measured by expanded disability status scale (EDSS) score, the time to onset of the first relapse, and the progression of neuroradiological lesions at 1 year of treatment.

Results At 1 year of treatment, the ARR dropped from 1.82 to 0.37 (p<0.0001). The mean EDSS score improved by 1.3 points, going from 5.8 at baseline to 4.5 at 1 year (p<0.0001). The number of patients showing gadolinium (Gad)+ spinal cord lesions at baseline, that is, 46.9%, dropped to 10.6% (a 77.4% reduction; p=0.02). The median time to onset of the first relapse was 18 months. IgG-NMO seropositivity was a predictive factor of relapse (p=0.006). A case of acute myeloid leukaemia was observed after a mean time span of 4.8 years.

Conclusions In this observational NMO study, MTX decreased dramatically the frequency of relapses, which is directly related to progression of disability or even death in this disorder.

  • MULTIPLE SCLEROSIS
  • MRI

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.